Clinical trial MCLA-128-CL02
Phase 2 study of MCLA-128-CL02 Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 2 |
Academic trial | Non |
Sponsor | Merus |
EudraCT Identifier | 2017-002821-39 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03321981 |
Inclusion criteria | 3rd to 5th line, FISH+ (IHC ++/+++), prior trastu/pertu &TDM1 |
Last update |